PLSE Earnings & Financial Statements
Pulse Biosciences, Inc.
$44.60
-$1.73(-3.72%)
49
Overall
40
Value
63
Tech
44
Quality
Market Cap
$3.30B
Volume
236.43K
52W Range
$12.56 - $58.90
Target Price
$56.50
PLSE earnings and financial statements: Pulse Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PLSE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $350.0K | - | - | $700.0K | $1.42M |
| Cost of revenue | $539.0K | - | - | $11.94M | $1.97M |
| Operating income | -$76.94M | -$56.26M | -$43.57M | -$58.06M | -$63.01M |
| EBITDA | -$74.75M | -$57.17M | -$41.05M | -$56.70M | -$61.87M |
| Net income | -$72.78M | -$53.59M | -$42.21M | -$58.51M | -$63.66M |
| EPS (diluted) | $-1.08 | $-0.92 | $-0.88 | $-1.72 | $-2.28 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $94.54M | $132.46M | $59.15M | $77.88M | $54.25M |
| Total liabilities | $13.88M | $17.60M | $14.79M | $80.13M | $18.56M |
| Shareholders’ equity | $80.66M | $114.86M | $44.36M | -$2.25M | $35.69M |
| Cash and equivalents | $80.73M | $118.04M | $44.37M | $61.14M | $28.61M |
| Long-term debt | $5.96M | $7.54M | $8.09M | $74.14M | $10.04M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$54.12M | -$36.34M | -$33.04M | -$47.01M | -$54.10M |
| Capital expenditure | -$335.0K | -$125.0K | -$121.0K | -$401.0K | -$437.0K |
| Free cash flow | -$54.46M | -$36.47M | -$33.16M | -$47.41M | -$54.53M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PLSE | $44.60 | -3.7% | 236.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |